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ABSTRACT 
 
Purpose: Symptoms of dry eye are commonly reported in contact lens wearers 
and are a frequent cause of non-tolerance. The purpose of the present study is to 
evaluate the effects of oral treatment with particular omega-6 fatty acids in the 
form of evening primrose oil (EPO) on subjective symptoms, ocular surface signs 
and tear film characteristic in contact lens wearers with contact lens associated 
dry eye. Methods:  The study design was randomised, double-masked and 
placebo controlled. 76 female patients were treated for 6 months with either EPO 
or placebo (olive oil). Patients underwent 3 examinations (baseline, 3 months 
and 6 months). At each examination patients were given a questionnaire relating 
to lens comfort and dry eye symptoms and underwent a series of tests of tear 
film characteristics (tear meniscus height, break-up time), Meibomian gland 
function (lipid layer thickness and quality) and ocular surface parameters 
(hyperaemia and staining). Results: The EPO group showed a significant 
improvement in the specific symptom of ‘dryness’ at 3 and 6 months (p<0.01) 
and also a significant improvement in overall lens comfort at 6 months (p<0.01). 
Tear meniscus height was increased in the EPO group at 6 months relative to 
baseline (p<0.01), although all other objective signs were unchanged.  
Conclusion: This study provides evidence for a beneficial effect of particular 
orally administered omega-6 fatty acids in alleviating dry eye symptoms and 
improving overall lens comfort in patients suffering from contact lens associated 
dry eye.  
Keywords:
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INTRODUCTION 
A sensation of ‘dryness’ is a commonly reported symptom in contact lens 
wearers [1, 2] and is a frequent cause of reduced wearing times or 
discontinuation of wear [3]. The presence of a contact lens on the eye can have 
an adverse affect on tear physiology by increasing the rate of evaporation and 
decreasing tear break-up time [4, 5, 6].  The magnitude of the effect is influenced 
by variables such as lens material, care regime and environmental conditions [7, 
8, 9]. In the majority of cases of contact lens-induced dry eye objective signs are 
lacking and a diagnosis is based on symptoms alone. However, a recent study 
has demonstrated that intolerant contact lens wearers show significantly reduced 
tear stability and volume compared to successful wearers [10].  
 
Conventionally, a variety of management strategies have been used to alleviate 
contact lens-induced dry eye including: tear supplements [11, 12] changing lens 
parameters [13] or tear preservation with punctal plugs [14, 15]. However, novel 
treatment strategies that advocate the use of anti-inflammatory or 
immunomodulatory agents may also be appropriate. This approach is based on 
evidence for a putative role of inflammation of the lacrimal functional unit 
(lacrimal gland and ocular surface) in the pathogenesis of many forms of dry eye 
[16, 17]. The immunomodulatory drug cyclosporine, that specifically inhibits T-
lymphocyte proliferation, was approved by the FDA in 2002 as a treatment for dry 
eye. Randomized placebo-controlled trials have shown that cyclosporine 
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ophthalmic emulsion is superior to vehicle in stimulating aqueous tear production 
in patients with keratoconjunctivitis sicca (KCS) [18].  Moreover, a recent pilot 
study offers evidence that cyclosporine may also be beneficial in contact lens 
intolerant patients [19]. 
 
Dietary modification or supplementation with essential fatty acids (EFAs) 
represents an alternative therapeutic strategy for dry eye. EFAs act as 
precursors for the synthesis of eicosanoids (prostaglandins, thromboxanes and 
leukotrienes) that regulate many aspects of the inflammatory process. By altering 
the EFA content of the diet, or administering particular EFAs as supplements, it is 
possible to modify the balance between pro and anti-inflammatory mediators 
[20]. The synthesis of inflammatory eicosanoids from their precursor EFAs is 
shown in Figure 1.  2-series prostaglandins and 4-series leukotrienes, which 
derive from arachidonic acid (AA) via the enzymes cyclooxygenase (COX) and 5-
lipoxygenase (5-LOX) respectively, have proinflammatory effects e.g. pain, 
vasodilation and leukocyte recruitment.  Dietary omega-3 fatty acid 
supplementation e.g. eicosapentaenoic acid (EPA), can reduce the production of 
these AA-derived mediators via a process of competitive enzyme inhibition, 
thereby shifting the balance to a less inflammatory state [20].  
 
An alternative therapeutic approach involves the use of specific omega 6 EFA 
supplements [21]. Several studies have shown that gamma-linoleic acid (GLA), 
which is found in high concentration in oils derived from evening primrose 
(Oenothera biennis), has anti-inflammatory properties. GLA elevates dihomo-γ-
linolenic acid (DGLA) concentrations, leading to an increased synthesis of 1-
series prostaglandins that have a negative feedback role in chronic inflammation 
[21].  DGLA can also suppress the production of 2-series prostaglandins and 4-
series leukotrienes via enzyme inhibition. Clinical studies have demonstrated that 
dietary supplementation with GLA and its precursor linoleic acid (LA) produces 
symptomatic relief in systemic diseases that are characterised by chronic 
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inflammation such as rheumatoid arthritis [22]. Recently, therapy with GLA and 
LA has also been shown to reduce ocular surface inflammation and improve 
symptoms in patients with dry eye syndrome with an inflammatory component 
[23, 24]. 
 
The purpose of the present study is to evaluate the effects of oral treatment with 
particular omega-6 fatty acids in the form of evening primrose oil (EPO) on 
subjective symptoms, ocular surface signs and tear film parameters in contact 
lens wearers with contact lens associated dry eye.  
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MATERIALS AND METHODS 
Subject recruitment  
76 Female soft contact lens wearers (Table 1) were recruited into the trial based 
either on their responses to a McMonnies dry eye history questionnaire indicating 
that they were suffering from dry eye or borderline dry eye (Mc Monnies score 
>=10) or that they were experiencing symptoms of contact lens-induced dry eye. 
All patients who took part in the trial were wearing monthly or daily soft contact 
lenses. The lens types worn were divided into 4 groups, of which group 1 were 
silicone hydrogel lenses and groups 2 to 4 were separated according to FDA 
categories. The average wearing time of the contact lenses was calculated as 
hours per week. All subjects gave informed signed consent and the study was 
approved by the City University Research and Ethical Committee. Guidelines of 
the Declaration of Helsinki were adhered to. 
Experimental design 
This trial was longitudinal, double masked and placebo controlled. Subjects were 
randomly allocated to one of two groups. Each group was treated for a 6 month 
period with six capsules per day containing either LA/GLA in the form of EPO or 
a placebo, which was olive oil. Subjects were instructed not to change their diet, 
nor take any additional dietary supplements, for the duration of the study. 
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The active and placebo capsules were both supplied by Equazen (Equazen UK 
Ltd, London). The contents of the EPO capsules (Qarma™) used in the trial were 
LA 72.6%, GLA 10.5%, palmitic acid 6.5%, oleic acid 6.4% and stearic 
acid 1.8%. Each capsule contained 50 mg of GLA. The contents of the olive oil 
were 78.0% C18:1 (mainly oleic acid), 11.2% C16:0 (palmitic acid) and 5.6% 
C18:2 (mainly linoleic acid). Before encapsulation 1.6 mg natural tocopheryl 
(vitamin E) was added to both active and placebo to protect the contents of the 
capsule from oxidative damage. The olive oil capsules were made to taste, smell 
and appear the same as the active capsules. The capsules were loaded into 
standard unmarked tablet jars with a four-digit identifier code. Codes were 
allocated to one of two treatment groups (1 or 2), using an online random 
sequence generator. Coding, labelling and randomisation were carried out by the 
supplier and codes were not broken until the analysis was complete.  
Experimental procedures 
Subjects were evaluated at baseline and at three and six months during which 
the following procedures were carried out. 
Symptoms questionnaire 
Two visual analogue scales were designed. Firstly, lens comfort was graded on a 
scale from 1 to 10 (1=uncomfortable, to 10=no discomfort). Secondly each of the 
following symptoms was graded individually on a scale from 0 to 10 (0=no 
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symptoms to 10=extreme symptoms): soreness, scratchiness, dryness, 
grittiness, burning. 
Tear meniscus height 
The inferior tear meniscus height (TMH) was assessed with the slit lamp and 
recorded in mm. 
Ocular surface health 
Bulbar and palpebral conjunctival hyperaemia was assessed, together with 
fluorescein staining of the cornea and conjunctiva. The CCLRU decimalised 
grading scale was used for grading (1=very slight, 2=slight, 3=moderate, 
4=severe) [25]. The van Bijsterveld score was used to grade the rose bengal 
staining of the cornea and conjunctiva (0=no staining to 3=confluent staining) 
[26]. 
Meibomian gland assessment 
The quality and quantity of Meibomian secretions were measured by manual 
expression. The quantity was graded using a 3-point scale: 0=normal, 1=delay 
2= partially blocked and 3=blocked. The quality was similarly graded:  0=clear, 
1=cloudy, 2=granular, 3=opaque solid. 
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Lipid layer evaluation 
The lipid layer was assessed on its appearance under specular reflection using 
the Keeler Tearscope Plus®. (Keeler Ltd, UK) The lipid layer was graded 
according to the Guillon Scale into five different interference patterns (1= 
meshwork, 2=wave, 3=amorphous, 4=colour fringes (1st order), 5=colour fringes 
(2nd order) [27]. 
Tear break-up time 
The non invasive break-up time (NIBUT) was assessed using the Tearscope and 
fluorescein break-up time (BUT) was measured using conventional methodology. 
An average of three readings was taken in each case and the time in seconds 
from the blink to the first break noted. 
Statistical analysis 
Within group objective and subjective data were analysed using a non-parametric 
2-way analysis of variance (ANOVA) test (Friedman). The Mann Whitney test 
was used for between group comparisons. Due to multiple testing across many 
parameters and the possibility of finding effects by chance, a inflammation such 
as rheumatoid arthritis [22]. Recently, therapy with GLA and LA has also been 
shown to reduce ocular surface inflammation and improve symptoms in patients 
with dry eye syndrome with an inflammatory component [23, 24]. 
 
The purpose of the present study is to evaluate the effects of oral treatment with 
particular omega-6 fatty acids in the form of evening primrose oil (EPO) on 
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subjective symptoms, ocular surface signs and tear film parameters in contact 
lens wearers with contact lens associated dry eye p-value of less than 0.01 was 
considered as statistically significant. 
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RESULTS 
Of the 76 contact lens wearers recruited, 52 completed the trial (Placebo N=24, 
EPO N=28). The principal reason for drop out was non-compliance. All subjects, 
including dropouts, were included in the statistical analysis. Missing data was 
incorporated using the ‘last observation carried forward’ [28]. 
Demographics for all patients are shown in Table 1. 
The median McMonnies score for all the study subjects was 13. Scores indicative 
of borderline dry eye (10-20) were found in 69% of subjects with 6% recording a 
score indicative of a more severe dry eye (>20). Although all subjects 
subjectively complained of symptoms of dry eye, 25% of subjects had a 
McMonnies score of <10. There was no significant difference in dry eye severity 
between the EPO group and the placebo group.  
The EPO group had an average wearing time of 71.9 hours per week (SD 21.6 
hours) and the placebo group had an average wearing time of 75.6 hours (SD 26 
hours). This difference was not significant. The lens types worn by the subjects 
during the trial also showed no significant difference between groups (Table 1). 
The overall contact lens comfort at six months for the EPO group showed an 
approximately 20% improvement compared to baseline (p< 0.01) (Figure 2). No 
significant changes in lens comfort were found for the placebo group. In terms of 
individual symptom scores, the EPO group showed a significant reduction in the 
symptom of ‘dryness’ at both three and six months (p<0.01) (Figure 3). Both 
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groups showed no significant differences in all other individual symptom scores 
after three and six months.  
Compared to baseline, measures of tear quality and stability, together with 
indicators of ocular surface health (e.g. hyperaemia and staining) did not show 
any significant differences at three and six months. Similarly there were no 
differences in meibomian gland secretions or lipid layer morphology.  By contrast, 
the EPO group showed a significant increase in TMH after six months of EPO 
compared to baseline (p<0.01) (Figure 4).  
EPO and placebo were well tolerated and no significant adverse reactions were 
reported. 
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DISCUSSION 
The present study found that dietary supplementation with the EPO-derived 
omega-6 EFAs LA and GLA ameliorated symptoms and improved overall lens 
comfort in female patients with contact lens associated dry eye.  
Supplementation also caused a significant increase in tear production, as defined 
by tear meniscus height. It is reasonable to assume that the observed clinical 
improvement is primarily due to the well documented anti-inflammatory effects of 
these essential fatty acids [21].  
 
Sub-clinical inflammation has been demonstrated in contact lens wearers, based 
on numbers of polymorphonuclear leukocytes [29], tear cytokine profile [29] and 
increased expression of the inflammatory markers HLA -DR and ICAM-1 on 
ocular surface epithelia [30]. HLA-DR is a MHC class II antigen whose 
expression by conjunctival epithelial cells has been shown to correlate with the 
severity of dry eye, as characterised by vital staining and Schirmer test 
[31,32,33]. Contact lens wearers with dry eye show greater expression of HLA-
DR compared to non-dry eye wearers [34]. 
 
Recent studies have shown the beneficial effect of oral omega-6 
supplementation (LA and GLA) in Sjögrens and dry eye syndrome with an 
inflammatory component [23,24]. Reduced symptoms of dry eye were reported, 
as well as an improvement in objective signs such as corneal staining and 
reduced conjunctival expression of HLA-DR. Supplementation with LA and GLA 
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has also been shown to increase tear production and reduce dry eye symptoms 
after photorefractive keratectomy (PRK) [35]. 
 
 
The present study similarly showed a reduction in the specific symptom of 
‘dryness’, which was reduced by 40%. Although tear production was increased, 
other objective assessments e.g. ocular surface integrity and tear film quality 
were unaltered.  Our sample size is not large enough to completely rule out that 
some effects may have gone undetected, although the magnitude of the 
observed non-significant effects in this sample suggests that changes would not 
be beyond measurement variability or be clinically significant.  Furthermore, 
patients with contact lens associated dry eye typically display few clinical signs, 
even in the presence of marked symptoms.  The study patients likewise showed 
minimal conjunctival hyperaemia and good ocular surface integrity at baseline 
and there was little or no suggestion of poor tear quality or quantity.  
 
 
The anti-inflammatory effects of EPO are thought to be mediated by two principal 
mechanisms. The first involves a direct action of its component EFAs on immune 
cells. In-vitro studies have shown that the administration of LA and GLA 
suppresses T-cell activation by interfering with signal transduction [36]. The 
second mechanism is via their effect on eicosanoid synthesis. GLA is 
metabolised to DGLA, which inhibits the synthesis of pro-inflammatory cytokines 
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e.g. LT4 and PGE2  by competing with AA for COX and inhibiting 5-LOX via the 
15-hydroxyl intermediate 15-hydroxyeicosatrienoic acid (15-HETE) [21]. DGLA is 
also metabolised to 1-series prostaglandins such as PGE1 which has 
demonstrable anti-inflammatory effects at the ocular surface [37]. Furthermore, 
PGE1 has also been shown to increase aqueous tear secretion via a presumed 
action on lacrimal adrenergic receptors leading to cyclic nucleotide synthesis 
[38].  
 
Dietary supplementation with LA and GLA in patients with primary Sjögrens 
syndrome, at a lower dose than in the present study, elevates both plasma DGLA 
[39] and leads to raised  PGE1 levels in tears [24] in line with an improvement in 
ocular surface signs and symptoms. A similar mechanism could therefore explain 
the observed symptomatic improvement in the EPO group. A significant increase 
in tear meniscus height was also seen in the treatment group at 6 months 
compared to pre-trial values and a smaller increase in the placebo group 
(although this did not reach the 1% level of significance).  The placebo used in 
the current study was olive oil. The choice of a truly inactive placebo can be 
problematic in randomised placebo-controlled trials of this nature [21] and 
therefore the possibility that olive oil influences tear secretion cannot be 
completely ruled out. Although olive oil contains predominantly oleic acid, an 
omega-9 fatty acid, it also contains a small quantity of LA, which in the body can 
be converted into GLA via the enzyme delta-6 desaturase and thus influence tear 
secretion by the same mechanism. Furthermore, olive oil has been recently 
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shown to contain a natural anti-inflammatory compound which displays a potency 
and pharmacological profile similar to ibuprofen [40]. 
 
Whilst the present study has provided evidence for the beneficial effect of LA and 
GLA in dry eye, other omega 6 EFAs may be deleterious e.g. a diet rich in AA 
can lead to an excessive production of proinflammatory mediators.  For optimal 
nutrition, an appropriate balance should be maintained between omega-6 and 
omega-3 EFA consumption [41]. Western diets tend to be deficient in omega-3, 
particularly those derived from fish, which may promote the development of 
several chronic diseases, including dry eye [41]. Significantly, Miljanovich and co-
workers found that dietary ratios of omega-6 to omega-3 EFAs in excess of 15:1 
were associated with an increased risk of dry eye syndrome [42]. Omega 3 EFAs 
reduce the levels of AA-derived inflammatory mediators as well as maintaining 
the conversion of DGLA into anti-inflammatory 1-series prostaglandins.   
 
There is evidence that omega-3 supplementation may independently be of 
benefit in the management of dry eye. A recent large epidemiological study 
involving 39,876 women in the USA found that higher intake of omega-3 fatty 
acids in the diet is associated with a decreased incidence of dry eye syndrome. 
Women who consumed at least five servings of tuna per week were at a 68% 
reduced risk of dry eye syndrome, compared to women who had one serving per 
week [42].  
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In conclusion, this study provides evidence for a beneficial effect of particular 
orally administered omega-6 fatty acids in alleviating symptoms and improving 
overall lens comfort in patients suffering from contact lens associated dry eye. It 
is likely that this is via a reduction in ocular surface inflammation that has been 
previously documented in contact lens wearers. A secondary effect on tear 
secretion may also be a contributing factor. When advising patients regarding 
EPO supplementation, the importance of omega-3 EFA intake should also be 
discussed. Future studies will investigate the efficacy of a combined preparation, 
since it is likely that omega-3 fatty acids could act synergistically with omega-6 to 
enhance the therapeutic effect of each EFA.  
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TABLES 
 
Patient demographics  EPO Placebo 
Wearing time (mean (SD) in hours)  71.9 (21.6) 75.6 (26.0) 
Age (mean (SD) in years)  46.4 (12.6) 37.3 (10.7) 
Lens type (proportions in each FDA 
category as %) 
Group 1 0 3 
Group 2 74 64 
Group 3 0 0 
Group 4 26 33 
McMonnies score (proportions in each 
category as %) 
< 10 20 30 
10-20 74 64 
>20 6 6 
 
Table 1. Patient demographics 
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FIGURES 
Figure 1-Metabolism of EFAs to prostaglandins and leukotrienes. Dietary omega-
6 EFAs linoleic acid and gamma linolenic acid are metabolised to dihomo-
gamma linolenic acid (DGLA), resulting in an increased synthesis of anti-
inflammatory 1-series prostaglandins. DGLA can be converted at a slow rate to 
arachidonic acid. The omega-3 amino acid eicosapentaenoic acid (EPA) 
competitively inhibits pathways leading to AA-derived proinflammatory. Solid 
lines represent synthetic pathways, broken lines represent enzyme inhibition. 
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Figure 2 - Overall contact lens comfort for the EPO and placebo group based on 
a 10-point visual analogue scale (1= uncomfortable, 10= no discomfort). Values 
represent means ±SD. *P<0.01 (Friedman 1-way ANOVA).  
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Figure 3 – Mean symptom score for ‘dryness’ for the EPO and placebo group 
based on a 10-point visual analogue scale (1= no symptoms 10= extreme 
symptoms). Values represent means ± SD. *P<0.01 (Friedman 1-way ANOVA) 
using a 10-point visual analogue scale  
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 Figure 4 – Tear meniscus height  for the EPO and placebo group (means ± SD). 
*P<0.01 (Friedman 1-way ANOVA) 
 
 
